Advances in Reproductive Sciences

Volume 4, Issue 2 (May 2016)

ISSN Print: 2330-0744   ISSN Online: 2330-0752

Google-based Impact Factor: 0.33  Citations  

An Update on Pathophysiology and Medical Management of Endometriosis

HTML  XML Download Download as PDF (Size: 2304KB)  PP. 53-73  
DOI: 10.4236/arsci.2016.42008    2,799 Downloads   5,953 Views  Citations

ABSTRACT

Endometriosis is an inflammatory oestrogen dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The modern advance in treatment of endometriosis management is tackling the debilitating pain it causes, besides the infertility in patients desiring fertility in reproductive age group. This can be achieved by surgical or medical means, although in most cases a combination of both treatments is required. Usually, long term treatment is required in most cases. Unfortunately in most cases, pain symptoms recur between 6months and 12 months once treatment is stopped. A lot of research has gone in understanding the pathogenesis and further medical management of endometriosis besides surgery to be useful in relieving pain and use in patients desiring fertility besides hormonal treatments used earlier like hormonal contraceptives (oral, transdermal or vaginal administration), progestogens, danazol, Gonadotrophic releasing hormone agonist (GnRH), aromatase inhibitors. Newer agents like antiangiogenic drugs, phytochemical agents like resveratrol, TNF-α inhibitors, GnRH antagonists like egalogolix, statins, antiinflammatory agents like COX2 Inhibitors and PPARγ inhibitors like pioglitazone etc., with recent work of combined efficacy of telmesartan of both PPARγ partial agonism along with angiotensin 1 receptor agonism having more efficacy, role of immunomodulators like rapamycin, lipoxin 4 and pentoxyphylline, GnRH antagonists like egalogolix are still under study undergoing phase III trials although preliminary results show promising results with fewer side effects as compared to similar duration of GnRH agonist and much less BMD side effects. Increasing number of trials show the safety of SPRM’s, along with efficacy although disadvantage is suppression of fertility so cannot be used for women desiring fertility. Currently, only mifepristone and ulipristal have received FDA approval for indication in fibroid treatment, MTP and not for endometriosis as yet. The advantages and disadvantages of all the recent advances are discussed in an update in the pathophysiology as well medical treatment of endometriosis.

Share and Cite:

Kaur, K. and Allahbadia, G. (2016) An Update on Pathophysiology and Medical Management of Endometriosis. Advances in Reproductive Sciences, 4, 53-73. doi: 10.4236/arsci.2016.42008.

Cited by

[1] How performing Single frozen blastocyst transfer might obviate the earlier anticipated problems in infertility related to Endometriosis-A
2021
[2] The potential effect of fucoidan on inhibiting epithelial-to-mesenchymal transition, proliferation, and increase in apoptosis for endometriosis treatment: In vivo and in …
2020
[3] Different nutrient intake and prevalence of gastrointestinal comorbidities in women with endometriosis
2019
[4] USO DEL DIENOGEST EN EL MANEJO MEDICO DE LA ENDOMETRIOSIS Y ADENOMIOSIS EN UNA POBLACION DE MUJERES CARTAGENERAS
2017
[5] Current Controversies and Future Directions for Endometriosis Therapy
2017
[6] Should All Patients With Endometriosis Undergo Surgery?
2017
[7] Period repair manual: Natural treatment for better hormones and better periods
2017

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.